Sage Therapeutics to lay off about 40 percent of its workforce
The job cuts come after the FDA gave only limited approval to the Cambridge company’s new treatment for depression.
Stay updated with breaking news from Al Robichaud. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The job cuts come after the FDA gave only limited approval to the Cambridge company’s new treatment for depression.
By Colin Kellaher Sage Therapeutics plans to slash 40% of its workforce in a restructuring after the biopharmaceutical company and partner Biogen failed to...
The cuts, including several C-suite exits, come in the wake of the FDA’s decision not to approve Sage and partner Biogen’s drug for major depression.
Thursday’s 10 a.m. Concord-Carlisle/Lexington game is being prepared for with the usual special treatment. It’s not only the rebirth of a long-played series.